Aspiriant Risk-Managed Equity Allocation Fund Advisor Shares RMEAX Fund Analysis

| Medalist Rating as of | See Aspiriant Investment Hub

Morningstar’s Analysis RMEAX

Will RMEAX outperform in the future?

Get our overall rating based on a fundamental assessment of the pillars below.

null Morningstar Automated Analysis

Morningstar Automated Analysis

Summary

Aspiriant Risk-Managed Equity Allc Adv holds a quantitatively derived Negative Morningstar Medalist Rating. The rating indicates the model sees limited potential for the strategy to outperform peers on a risk-adjusted basis over a full market cycle.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Sponsor Center